Minerva (NERV) announced that the first patient has been screened in its global, confirmatory Phase 3 clinical trial evaluating roluperidone as monotherapy for the treatment of negative symptoms of schizophrenia.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NERV:
- Why Is the VTI ETF Down Today? Daily Snapshot – 3/12/26
- Minerva price target raised to $7 from $4 at H.C. Wainwright
- Minerva Neurosciences Warns of Major Dilution Risk From Preferred Stock Conversions and Warrant Exercises
- Minerva files $200M mixed securities shelf
- Vanguard Total Stock Market ETF (VTI) Daily Snapshot—3/11/26